Humabiologics
Develops and supplies native human-derived biomaterials (collagen, gelatin, ECM, bioinks) for 3D bioprinting and regenerative medicine, enabling clinically relevant tissue models and therapies.
- CEO / Founder
- Mohammad Albanna
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $1M
- Latest Round
- Seed
- Key Investors
- National Science Foundation’s (NSF) Regenerative Medicine Engine
Technology & Products
Key Products
Human collagen; Human gelatin; Extracellular matrices (ECM); Bioinks (e.g., OsteoGelMa); Coated cultureware
Technological Advantage
Proprietary processes for producing soluble and insoluble collagen from human dermis tissue, protected by patents (e.g., US patents for collagen production), ensuring defensible IP and superior clinical relevance.
Differentiation
Value Proposition
Provides affordable, high-quality human-derived biomaterials with superior biocompatibility vs. animal-derived alternatives, reducing research costs and accelerating translation to clinical applications.
How They Differentiate
Offers native human-derived biomaterials (vs. plant-based or marine alternatives) with FDA-compliant sourcing from tissue banks, providing higher biocompatibility and clinical relevance for 3D bioprinting applications.
Market & Competition
Target Customers
Research laboratories, academic institutions, biotech companies, and healthcare professionals in regenerative medicine and tissue engineering.
Industry Verticals
Regenerative Medicine; Tissue Engineering; 3D Bioprinting; Pharmaceutical Research; Cell Culture
Competitors
CollPlant; Advanced BioMatrix; Jellagen
Growth & Milestones
Growth Metrics
Secured $1M seed funding; expanded to Winston-Salem, North Carolina with a $2.5M NSF grant; ships products globally to over 10 countries.
Major Milestones
Founded in 2018; Launched first human bone gelatin in 2019; Raised $1M seed round; Secured two patents for biomaterial production; Expanded to North Carolina in 2025; Partnerships with key bioprinting companies